TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Antiretroviral Activity of MK-0518 Versus Efavirenz in Treatment Naive HIV-Infected Patients, Each in Combination With TRUVADA (0518-021 EXT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participant is a male or female at least 18 years of age~* Participant is HIV positive~* Participant is naïve to antiretroviral therapy (ART) and has not received any ART~Exclusion Criteria:~* Participant has received approved or experimental antiretroviral agents in the past~* Participant has been treated for a viral infection other than HIV such as hepatitis B virus infection with an agent that is active against HIV including but not limited to adefovir or lamivudine (= 7 days total)~* Participant has documented resistance to tenofovir, emtricitabine, and/or efavirenz~* Participant has used another experimental HIV-integrase inhibitor~* Participant has a current (active) diagnosis of acute hepatitis due to any cause~* Participants with chronic hepatitis including chronic hepatitis B and/or C may enter the study as long as they have stable liver function tests

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MK-0518 400 mg b.i.d. (Type: EXPERIMENTAL): MK-0518 400 mg, which can be taken by mouth (PO) twice a day (b.i.d.) without regard to food, and placebo to efavirenz, which will be taken PO at bedtime (q.h.s.) on an empty stomach preferably at bedtime. All participants will take one tablet of TRUVADA® (200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate) with food, daily with the morning dose of MK-0518. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.
- Efavirenz 600 mg q.h.s. (Type: ACTIVE_COMPARATOR): Efavirenz 600 mg, which will be taken by mouth (PO) at bedtime (q.h.s.) on an empty stomach preferably at bedtime, and placebo to MK-0518, which will be taken PO twice a day (b.i.d.) without regard to food. All participants will take one tablet of TRUVADA® with food, daily with the morning dose of placebo. Dosing interval adjustment of TRUVADA® is recommended in all participants with creatinine clearance 30-49 mL/min.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Having end-stage renal disease (ESRD) on maintenance hemodialysis~* Aged between 18 and 70 years at enrollment~* Serologically negative for hepatitis B surface antigen (HBsAg) and hepatitis B surface antibody (anti-HBs) at enrollment~* Willing to adhere to the study protocol~Exclusion Criteria:~* Being pregnant~* Acute cytolysis in the last three months before enrollment~* Any vaccination during the month preceding enrollment~* Intolerance or allergy to any component of the vaccine~* Ongoing opportunistic infection~* Hepatitis C virus infection~* Hematological disorder~* Cancer~* Unexplained fever the week before enrollment~* Immunosuppressive or immunomodulating treatment in the last six months~* Renal transplantation or upcoming renal transplantation~* Liver disease~* Other immunocompromised condition not related to ESRD~* An expected survival of \< 6 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 60 µg dose hepatitis B vaccine (Type: EXPERIMENTAL): 60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6
- 20 µg dose hepatitis B vaccine (Type: EXPERIMENTAL): 20 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sphenopalatine Ganglion Block for Nasal Surery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patient written consent~* elective surgery~* age 18 - 55 year old~Exclusion Criteria:~* patient refusal~* emergency surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- bupivacaine group (Type: ACTIVE_COMPARATOR): None
- saline group (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Quickstart of Nexplanon® at Medical Abortion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women opting for medical abortion and post abortion Nexplanon~* no contraindicated to medical abortion or Nexplanon (according to the SMPc) gestational length up to and including 63 days (determined with ultrasonography)~* able and willing to provide informed consent~Exclusion Criteria:~* unwilling to participate,~* unable to communicate in Swedish and English and~* minors (i.e. women \< 18 years of age),~* contraindications to Nexplanon®~* women with pathological pregnancies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Etonorgestrel and mifepristone (Type: EXPERIMENTAL): Quickstart, insertion of Nexplanon on the day of mifepristone in medical abortion
- mifepristone (Type: ACTIVE_COMPARATOR): Mifepristone on day 1. Nexplanon insertion at 3 weeks FU after the medical abortion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and Reactogenicity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Child healthy (stable chronic conditions acceptable) as established by health assessment interview and verbal history-directed health examination~* Child between and including 6 months of age and 23 months of age (up to and including the day before 24 months of age)~* Child is available and can complete all relevant procedures during the entire study period~* Parent or legal guardian is available and can be reached by phone during the entire study period~* Parent/guardian provides written informed consent~* Parent/guardian is fluent in English~Exclusion Criteria:~* Child has history of laboratory-confirmed influenza~* Child has history of any prior influenza immunization~* Child has history of anaphylactic reaction to any component of the vaccine (i.e. egg)~* Child has received immune globulin or other blood products within the prior six weeks~* Child has received injected or oral steroids within the prior six weeks (inhaled or topical steroids allowed)~* Child has a bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate intramuscular injection (thrombocytopenia, coagulation disorder, anti-coagulant therapy)~* Child is or will be enrolled in any other clinical trial of a drug, vaccine or medical device during the study period~* Child is scheduled to receive a live vaccine (notably measles, mumps, rubella or varicella vaccines) during the study period~* Child has a health condition which, in the opinion of the investigator, would interfere with the evaluation or pose a health risk to the child

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 23 Months
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): 2 doses 0.5mL VAXIGRIP® at months 0, 1
- 2 (Type: ACTIVE_COMPARATOR): 2 doses 0.25mL VAXIGRIP® at months 0, 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females ages 6 up to 18~* ADHD diagnosis with ADHD Rating Scale - 4th Edition scores ≥ 90th percentile~* In need of treatment for ADHD and able to have 2-day washout from previous medication~* Females of child-bearing potential not pregnant and practice birth control~* Subject and parent/guardian willing to comply with protocol~* Signed consent and assent~Exclusion Criteria:~* Estimated Full Scale intellectual level below 80 using Wechsler Abbreviated Scale of Intelligence (WASI)~* Current primary psychiatric diagnosis of other listed disorders~* Chronic medical illnesses: seizure, hypertension, thyroid disease, cardiac, family history of sudden death, glaucoma~* Use of psychotropic central nervous system (CNS) meds having effect exceeding 14 days from screening~* Planned use of prohibited drugs~* Is pregnant or breast-feeding~* Significant ECG or laboratory abnormalities~* Experimental drug or medical device within 30 days prior to screening~* Hypersensitivity to methylphenidate~* Inability or unwillingness to comply with protocol~* Well controlled on current ADHD treatment~* Inability to take oral capsules

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 10 mg (Type: ACTIVE_COMPARATOR): Biphentin Methylphenidate Hydrochloride Extended Release Capsules 10 mg
- 15 mg (Type: ACTIVE_COMPARATOR): Biphentin Methylphenidate Hydrochloride Extended Release Capsules 15 mg
- 20 mg (Type: ACTIVE_COMPARATOR): Biphentin Methylphenidate Hydrochloride Extended Release Capsules 20 mg
- 40 mg (Type: ACTIVE_COMPARATOR): Biphentin Methylphenidate Hydrochloride Extended Release Capsules 40 mg
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules
- Methylphenidate HCl ER Capsules (10, 15, 20, 40, 50 or 60 mg) (Type: EXPERIMENTAL): Biphentin Methylphenidate Hydrochloride Extended Release Capsules (10, 15, 20, 40, 50 or 60 mg) - Open Label Phase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Isoflurane and Sevoflurane Comparison in Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be 18 years or over (There is no upper age limit to enrollment)~* Eligible procedures are: CABG on-pump or off-pump, single valve repair/replacement, or CABG/single valve combined procedures~Exclusion Criteria:~* Cardiac surgeries that are not one of the included cases~* Planned extubation in the operating room~* Patients refusing blood products (vis à vis blood sampling)~* Pregnant patients~* Malignant hyperthermia or documented/stated allergy to potent volatile anesthetic agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- sevoflurane (Type: ACTIVE_COMPARATOR): These patients will receive sevoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.
- isoflurane (Type: EXPERIMENTAL): These patients will receive isoflurane as the volatile anesthetic pre-, during-, and post-cardiopulmonary bypass at a targeted dose of 0.5-2.0 MAC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adjunctive Cilostazol Versus High Maintenance-dose Clopidogrel According to Cytochrome 2C19 Polymorphism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Significant coronary artery stenosis (\>70% by visual estimate)~* Elective coronary stent implantation~Exclusion Criteria:~* Acute myocardial infarction~* Active bleeding and bleeding diatheses~* Hemodynamic instability~* Oral anticoagulation therapy with warfarin~* Use of peri-procedural glycoprotein IIb/IIIa inhibitors~* Contraindication to antiplatelet therapy~* Left ventricular ejection fraction \< 30%~* Leukocyte count \< 3,000/mm3, platelet count \< 100,000/mm3, AST or ALT ≥ 3 times upper normal~* Serum creatinine level ≥ 3 mg/dL~* Stroke within 3 months~* Noncardiac disease with a life expectancy \< 1 year~* Inability to follow the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- adjunctive cilostazol (Type: ACTIVE_COMPARATOR): adjunctive cilostazol 100mg bid to dual antiplatelet therapy
- high maintenance-dose clopidogrel (Type: ACTIVE_COMPARATOR): double dose of clopidogrel 150mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Study of Abiraterone Acetate in Castration-resistant Prostate Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the prostate, but not with neuroendocrine differentiation or of small cell histology~* No Prior cytotoxic chemotherapy (including estramustine) for the treatment of prostate cancer~* Surgically or medically castrated, with testosterone levels of \< 0.5 ng/mL~* PSA level of at least 2 ng/ml at Screening~* PSA progression according to PCWG2 eligibility criteria or objective progression by RECIST criteria for patients with measurable disease after androgen deprivation~Exclusion Criteria:~* Surgery or local prostatic intervention within 4 weeks of the first dose. In addition, any clinically relevant sequelae from the surgery have not resolved prior to initial treatment~* Radiotherapy, or immunotherapy within 4 weeks, or single fraction of palliative radiotherapy within 2 weeks of administration prior to initial treatment~* Known brain metastasis~* Uncontrolled hypertension (systolic BP greater than 160 mmHg or diastolic BP greater than 95 mmHg)~* Active or symptomatic viral hepatitis or chronic liver disease

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): JNJ-212082 250 mg 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Rivaroxaban for the Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 20 years or older~* Japanese male or female~* Non- valvular atrial fibrillation documented by ECG~* Patients with a risk of stroke and non-CNS systemic embolism~Exclusion Criteria:~* Significant mitral stenosis~* Patients in whom anticoagulants are contraindicated

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Xarelto, BAY59-7939) (Type: EXPERIMENTAL): Participants received once daily (OD) a rivaroxaban 15 mg tablet and a warfarin placebo tablet during the double-blind treatment period
- Warfarin (Type: ACTIVE_COMPARATOR): Participants received OD a warfarin potassium tablet and a rivaroxaban placebo tablet during the double-blind treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Upper Facial Lines

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Provide written informed consent consistent with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines and local laws, including authorization to release health information, signed prior to any study procedures being performed~2. Be outpatient, male or female subjects, in good general health, 18 years of age or older~3. Have a score of moderate (2) or severe (3) Glabellar Lines during maximum contraction as assessed by the Investigator Global Assessment-Frown Wrinkle Severity (IGA-FWS) and Patient Frown Wrinkle Severity (PFWS)~4. Have a score of moderate (2) or severe (3) Forehead Lines during maximum contraction as assessed by the Investigator Global Assessment Forehead Wrinkle Severity (IGA-FHWS) and Patient Forehead Wrinkle Severity (PFHWS)~5. Have a score of moderate (2) or severe (3) Lateral Canthal Lines at maximum contraction as assessed by the Investigator Global Assessment of Lateral Canthal Wrinkle Severity (IGA-LCWS) and Patient Lateral Canthal Wrinkle Severity (PLCWS) (scores must be consistent bilaterally for each scale considered separately)~6. Able to understand the requirements of the study and be willing and able to follow all study procedures, attend all scheduled visits, comprehend and complete the questionnaires without outside assistance and successfully complete the study~Exclusion Criteria:~1. Active skin disease, infections, or inflammation at the injection sites~2. Planned or anticipated need for surgery or hospitalization through the end of the study~3. Pregnant, nursing, or planning a pregnancy during the study; or is a Women of Child Bearing Potential (WOCBP) but is not willing to use an effective method of contraception~4. Current enrollment in an investigational drug or device study or participation in such a study within the last 30 days prior to screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DAXI 40 U GL / 32 U FHL / 48 U LCL (Type: EXPERIMENTAL): DaxibotulinumtoxinA for injection for the treatment of moderate to severe Glabellar Lines (GL), Forehead Lines (FHL), \& Lateral Canthal Lines (LCL)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Dry Eye Using 0.03% Tacrolimus Eye Drops

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* SS was diagnosed according to the SS European Criteria~* chronic symptoms of burning, foreign body sensation, itching in both eyes~* daily need of artificial tears~* abnormal Schirmer (ST) I test \< 5mm or rose Bengal staining (RBS) ≥ 4, or break up time (BUT) \< 5 seconds.~Exclusion Criteria:~* any structural abnormalities (lid scarring, entropion, trichiasis, etc.)~* any inflammation or active structural change in the iris or anterior chamber~* glaucoma~* previous eye surgery or punctual occlusion~* use of any other topical medication other than artificial tears~* any systemic or topical antibacterial or antiinflammatory drug treatment 90 days before study entry~* contact lens wearer~* the presence of any corneal infection~* any corneal diseases (marginal ulcer, opacity, scar, bullous keratopathy, conjunctivochalasis, symblepharon or tumor)~* pregnancy~* change in the immunosuppressive systemic therapy 90 days before study entry

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- tacrolimus (Type: ACTIVE_COMPARATOR): tacrolimus 0,03% eye drops (olive oil as vehicle) every 12/12 hours for 3 months placebo as olive oil eye drops every 12/12h hours for 3 months
- Olive Oil (Type: PLACEBO_COMPARATOR): All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete